
Sign up to save your podcasts
Or
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD.
Related Content:
4.9
1212 ratings
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD.
Related Content:
133 Listeners
293 Listeners
162 Listeners
107 Listeners
493 Listeners
809 Listeners
278 Listeners
3,327 Listeners
17 Listeners
14 Listeners
23 Listeners
6 Listeners
90 Listeners
1,114 Listeners
29 Listeners
192 Listeners
289 Listeners
514 Listeners
349 Listeners
18 Listeners
364 Listeners
96 Listeners